Diabetes-Induced Birth Defects: What Do We Know? What Can We Do?

被引:52
|
作者
Reece, E. Albert [1 ]
机构
[1] Univ Maryland, Sch Med, Baltimore, MD 21210 USA
关键词
Antioxidant therapy; Birth defects; Fatty acid; Folic acid; Diabetic embryopathy; Dietary supplementation; Hyperglycemia; Infant mortality; Pregnancy; Glucose control; Molecular pathogenesis; Preconception care; Diabetes; INOSITOL POLYPHOSPHATES; CONGENITAL-ANOMALIES; SUPEROXIDE-DISMUTASE; INSULIN THERAPY; UNITED-STATES; EMBRYOPATHY; PREGNANCY; HYPERGLYCEMIA; PREVENTION; ACTIVATION;
D O I
10.1007/s11892-011-0251-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Birth defects are the leading cause of infant mortality in the United States, which has one of the highest infant mortality rates in the developed world. Many of these birth defects can be attributed to pre-existing, or pregestational, diabetes in pregnancy, which significantly increases a mother's risk of having a child with a major birth defect. Strict preconceptional and early pregnancy glucose control, supplementation with multivitamins and fatty acids, and lower glycemic dietary management have been shown to reduce the incidence of birth defects in experimental and epidemiologic studies. However, because more than half of pregnancies are unplanned, these methods are not generalizable across the population. Thus, better interventions are urgently needed. Based on what we know about the molecular pathophysiology of diabetic embryopathy, our laboratory and others are developing interventions against to key molecular targets in this multifactorial disease process.
引用
收藏
页码:24 / 32
页数:9
相关论文
共 50 条
  • [1] Diabetes-Induced Birth Defects: What Do We Know? What Can We Do?
    E. Albert Reece
    Current Diabetes Reports, 2012, 12 : 24 - 32
  • [2] Optimal Birth Spacing: What Can We Measure and What Do We Want to Know?
    Ahrens, Katherine A.
    Hutcheon, Jennifer A.
    PAEDIATRIC AND PERINATAL EPIDEMIOLOGY, 2018, 32 (02) : 149 - 151
  • [3] Osteoporosis and type 2 diabetes mellitus: what do we know, and what we can do?
    Abdulameer, Shaymaa Abdalwahed
    Sulaiman, Syed Azhar Syed
    Hassali, Mohamed Azmi Ahmad
    Subramaniam, Karuppiah
    Sahib, Mohanad Naji
    PATIENT PREFERENCE AND ADHERENCE, 2012, 6 : 435 - 448
  • [4] Menstruation in Adolescents: What Do We Know? and What Do We Do with the Information?
    Hillard, Paula J. Adams
    JOURNAL OF PEDIATRIC AND ADOLESCENT GYNECOLOGY, 2014, 27 (06) : 309 - 319
  • [5] What do we know about why women bleed and what do we not know?
    James, Andra H.
    James, Paula D.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2024, 22 (02) : 315 - 322
  • [6] The risk of viral transmission in feed: What do we know, what do we do?
    Dee, Scott A.
    Niederwerder, Megan C.
    Patterson, Gil
    Cochrane, Roger
    Jones, Cassie
    Diel, Diego
    Brockhoff, Egan
    Nelson, Eric
    Spronk, Gordon
    Sundberg, Paul
    TRANSBOUNDARY AND EMERGING DISEASES, 2020, 67 (06) : 2365 - 2371
  • [7] Zika virus infection and pregnancy: what we do and do not know
    Ticconi, Carlo
    Pietropolli, Adalgisa
    Rezza, Giovanni
    PATHOGENS AND GLOBAL HEALTH, 2016, 110 (7-8) : 262 - 268
  • [8] Pneumococcal conjugate vaccines: what do we know and what do we need?
    Schranz, Jennifer
    2ND GLOBAL CONGRESS ON VACCINES, 2009, 1 (01): : 189 - 205
  • [9] What do we know about perioperative hypersensitivity reactions and what can we do to improve perioperative safety?
    Kosciuczuk, Urszula
    Knapp, Pawel
    ANNALS OF MEDICINE, 2021, 53 (01) : 1772 - 1778